← Leaderboards
Gerald H. Friedland
Yale University
$7,221,288
Attributed
$7,399,868
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $802.5K · FY2005–13$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$7,399,868 · 4
By mechanism
U01$5,179,585 · 1
R01$1,828,587 · 1
R21$357,161 · 1
M01$34,535 · 1
Top collaborators
- Sheela Shenoi2 shared
Most similar at Yale University
Same institution · by research overlap
- Frederick Lewis Altice$47,021,698
- Lynn Madden$2,721,391
- John Lucian Davis$13,237,964
- Robert Heimer$22,887,831
- Adam Wisnewski$9,947,944
Others in their field
Top investigators on “Antiaids Agent”
- Constance Ann Benson · University Of California, San Diego$85,157,000
- Willard Cates · Family Health International$66,963,584
- Stephen A Spector · University Of California, San Diego$62,271,387
- Fred M Gordin · Social And Scientific Systems, Inc.$50,695,408
- Robert Turner Schooley · University Of Colorado Denver$46,857,922
- Douglas D Richman · University Of California San Diego$18,822,170
Research focus
Antiaids AgentHuman Therapy EvaluationClinical TrialsMethadoneHuman SubjectClinical ResearchCommunityAntiretroviral TherapyMorbidity - Disease RateLifeMortality Vital StatisticsEpidemicAnti-Retroviral AgentsDrug Screening /EvaluationAids TherapyBacteriaCytochrome P450Aids/Hiv ProblemCooperative StudyCountryDependency (Psychology)Antitubercular AgentsAreaCommunicable Diseases
Grant awards (16)
Implementing Point of Care CD4 Analysis to Decentralize HIV Care in Rural Africa$148,183
R21 · FY2013 · AI · contact PI
Drug Interactions in Substance Abusers with HIV Infection$357,593
R01 · FY2012 · DA · contact PI
Implementing Point of Care CD4 Analysis to Decentralize HIV Care in Rural Africa$208,978
R21 · FY2012 · AI · contact PI
Drug Interactions in Substance Abusers with HIV Infection$357,593
R01 · FY2011 · DA · contact PI
Drug Interactions in Substance Abusers with HIV Infection$368,651
R01 · FY2010 · DA · contact PI
Drug Interactions in Substance Abusers with HIV Infection$372,375
R01 · FY2009 · DA · contact PI
Drug Interactions in Substance Abusers with HIV Infection$372,375
R01 · FY2008 · DA · contact PI
NEW ENGLAND PROGRAM FOR AIDS CLINICAL TRIALS-PROACT (CPC$534,147
U01 · FY2006 · AI · contact PI
NEW ENGLAND PROGRAM FOR AIDS CLINICAL TRIALS-PROACT (CPC$802,493
U01 · FY2005 · AI
NEW ENGLAND PROGRAM FOR AIDS CLINICAL TRIALS-PROACT (CPC$802,495
U01 · FY2004 · AI
NEW ENGLAND PROGRAM FOR AIDS CLINICAL TRIALS-PROACT (CPC$802,496
U01 · FY2003 · AI
NEW ENGLAND PROGRAM FOR AIDS CLINICAL TRIALS-PROACT (CPC$780,910
U01 · FY2002 · AI
NEW ENGLAND PROGRAM FOR AIDS CLINICAL TRIALS-PROACT (CPC$759,265
U01 · FY2001 · AI
PHARMACOKINETIC EVALUATION OF METHADONE$0
M01 · FY2001 · RR
NEW ENGLAND PROGRAM FOR AIDS CLINICAL TRIALS-PROACT (CPC$697,779
U01 · FY2000 · AI
PHARMACOKINETIC EVALUATION OF METHADONE$34,535
M01 · FY2000 · RR